2015-04-08 Glycobond brings in new investors
Prominent private international business angels has together with Almi Invest invested in Glycobond for development of the company’s assay for diagnosis of liver cancer (HCC) at an early stage. The business angels has a background and knowledge within diagnostics and this is an important acknowledgment of Glycobond’s unique technology. The investment is an important step in the progress of the company and allows for the continued development of the assay.
-To develop a reliable method that can detect liver cancer at an early stage and also distinguish it from other diseases is a great challenge in combating HCC. It is very positive that we now get the opportunity to fulfill the work with development and launch of our assay, says Peter Påhlsson, CEO Glycobond.
2016-11-08 Glycobond finish second investment round
Glycobond’s announced the closing of the second investment round. The funding will enable the company to secure further development of HepaCheC, the new biomarker in liver cancer diagnostics. „We are very pleased with the progress of our first assay development project," commented Peter Pahlsson, CEO Glycobond. „We are on our way to launch HepaCheC ELISA and to start new clinical studies."